NewsDialy
A chief medical officer is the executive who decides how a drug company designs its clinical trials, interprets the data that comes back, and makes the medical case to regulators.
Spruce Biosciences has filled that seat, hiring Adrian Quartel, who held the identical title at Zevra Therapeutics before making the move. The CMO role sits at the center of any drug development program.
Whoever holds it shapes the scientific questions the company asks in its studies. Those questions, once locked into a trial design and filed with regulators, are largely fixed.
Changing course mid-study, or after a failed readout, is expensive. It resets timelines and burns runway. The hire matters because the CMO's choices determine what a company learns, and when.
Keep reading